Evaluation of a self-imaging SD-OCT system designed for remote home monitoring

被引:29
作者
Kim, Judy E. [1 ]
Tomkins-Netzer, Oren [2 ]
Elman, Michael J. [3 ]
Lally, David R. [4 ]
Goldstein, Michaella [5 ]
Goldenberg, Dafna [6 ]
Shulman, Shiri [6 ]
Benyamini, Gidi [7 ]
Loewenstein, Anat [5 ]
机构
[1] Med Coll Wisconsin, Eye Inst, 925 N 87th St, Milwaukee, WI 53226 USA
[2] Technion, Ruth & Bruce Rappaport Fac Med, Lady Davis Carmel Med Ctr, Dept Ophthalmol, Haifa, Israel
[3] Elman Retina Grp PA, Baltimore, MD USA
[4] New England Retina Consultants, Retina Res Inst, Springfield, MA USA
[5] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel
[6] Assuta Med Ctr, Tel Aviv, Israel
[7] Notal Vis, Tel Aviv, Israel
关键词
Age-related macular degeneration; HOME OCT; Home monitoring; TREAT-AND-EXTEND; MACULAR DEGENERATION; RETINAL FLUID;
D O I
10.1186/s12886-022-02458-z
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To compare identification rates of retinal fluid of the Notal Vision Home Optical Coherence Tomography (OCT) device (NVHO) when used by people with age-related macular degeneration (AMD) to those captured by a commercial OCT. Methods Prospective, cross-sectional study where patients underwent commercial OCT imaging followed by self-imaging with either the NVHO 2.5 or the NVHO 3 in clinic setting. Outcomes included patients' ability to acquire analyzable OCT images with the NVHO and to compare those with commercial images. Results Successful images were acquired with the NVHO 2.5 in 469/531 eyes (88%) in 264/290 subjects (91%) with the mean (SD) age of 78.8 (8.8); 153 (58%) were female with median visual acuity (VA) of 20/40. In the NVHO 3 cohort, 69 eyes of 45 subjects (93%) completed the self-imaging. Higher rates of successful imaging were found in eyes with VA >= 20/320. Positive percent agreement/negative percent agreement for detecting the presence of subretinal and/or intraretinal fluid when reviewing for fluid in three repeated volume scans were 97%/95%, respectively for the NVHO v3. Conclusion Self-testing with the NVHO can produce high quality images suitable for fluid identification by human graders, suggesting the device may be able to complement standard-of-care clinical assessments and treatments.
引用
收藏
页数:13
相关论文
共 17 条
  • [1] The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial
    Campochiaro, Peter A.
    Marcus, Dennis M.
    Awh, Carl C.
    Regillo, Carl
    Adamis, Anthony P.
    Bantseev, Vladimir
    Chiang, Yawen
    Ehrlich, Jason S.
    Erickson, Signe
    Hanley, William D.
    Horvath, Joshua
    Maass, Katie F.
    Singh, Natasha
    Tang, Fan
    Barteselli, Giulio
    [J]. OPHTHALMOLOGY, 2019, 126 (08) : 1141 - 1154
  • [2] Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration
    Chakravarthy, Usha
    Goldenberg, Dafna
    Young, Graham
    Havilio, Moshe
    Rafaeli, Omer
    Benyamini, Gidi
    Loewenstein, Anat
    [J]. OPHTHALMOLOGY, 2016, 123 (08) : 1731 - 1736
  • [3] HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
    Dugel, Pravin U.
    Koh, Adrian
    Ogura, Yuichiro
    Jaffe, Glenn J.
    Schmidt-Erfurth, Ursula
    Brown, David M.
    Gomes, Andre, V
    Warburton, James
    Weichselberger, Andreas
    Holz, Frank G.
    [J]. OPHTHALMOLOGY, 2020, 127 (01) : 72 - 84
  • [4] Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration
    Essex, Rohan W.
    Nguyen, Vuong
    Walton, Richard
    Arnold, Jennifer J.
    McAllister, Ian L.
    Guymer, Robyn H.
    Morlet, Nigel
    Young, Stephanie
    Barthelmes, Daniel
    Gillies, Mark C.
    [J]. OPHTHALMOLOGY, 2016, 123 (11) : 2393 - 2400
  • [5] FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
  • [6] Goldstein M., AAO 2019 SAN FRANC C
  • [7] Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
    Heier, Jeffrey S.
    Khanani, Arshad M.
    Ruiz, Carlos Quezada
    Basu, Karen
    Ferrone, Philip J.
    Brittain, Christopher
    Figueroa, Marta S.
    Lin, Hugh
    Holz, Frank G.
    Patel, Vaibhavi
    Lai, Timothy Y. Y.
    Silverman, David
    Regillo, Carl
    Swaminathan, Balakumar
    Viola, Francesco
    Cheung, Chui Ming Gemmy
    Wong, Tien Y.
    [J]. LANCET, 2022, 399 (10326) : 729 - 740
  • [8] Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Degeneration
    Keenan, Tiarnan D. L.
    Chakravarthy, Usha
    Loewenstein, Anat
    Chew, Emily Y.
    Schmidt-Erfurth, Ursula
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2021, 224 : 267 - 281
  • [9] Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
  • [10] Age-related macular degeneration
    Lim, Laurence S.
    Mitchell, Paul
    Seddon, Johanna M.
    Holz, Frank G.
    Wong, Tien Y.
    [J]. LANCET, 2012, 379 (9827) : 1728 - 1738